Author Archives: ADCS Admin

Noted Canadian neurologist to head up UC San Diego’s Alzheimer’s Disease Cooperative Study. Howard Feldman of University of British Columbia is known for seminal research in dementias.

Howard Feldman of University of British Columbia is known for seminal research in dementias; UC launches new $4 million Alzheimer’s disease initiative.

Are humans the only ones who are able to remember events that they had experienced and mentally time travel not only into the past but also the future? Or do animals have the same capacity?

The model developed by the three researchers Prof Markus Werning, Prof Sen Cheng and Prof Thomas Suddendorf differs from other approaches with regard to one major aspect: it suggests a new relationship between mental time travel and episodic memory.

Neurogranin, a CSF Biomarker for Synaptic Loss, is Found to Predict Progression from MCI to Alzheimer’s Disease

Levels of neurogranin, a cerebrospinal fluid (CSF) biomarker for synaptic loss, were elevated in patients with Alzheimer’s disease (AD) compared with cognitively normal individuals. Neurogranin levels also predicted progression from mild cognitive impairment (MCI) to AD dementia, researchers reported here on Monday at the Alzheimer’s Association International Conference (AAIC).

Stanford researchers identify iron-containing microglia in the brains of people with Alzheimer’s disease

Examining post-mortem tissue from the brains of people with Alzheimer’s disease, Stanford University School of Medicine investigators identified what appear to be iron-containing microglia in a particular part of the hippocampus, a key brain structure whose integrity is critical to memory formation.

Wonderful new changes happening at the ADCS.

Two UC San Diego Researchers to Lead Alzheimer’s Disease Cooperative Study.

A new study published in JAMA Psychiatry suggests that clinical depression is associated with a 30% increase in brain inflammation.

This finding provides the most compelling evidence to date of brain inflammation, and more specifically microglial activation, in MDE. The correlation between higher ACC TSPO VT and the severity of MDE is consistent with the concept that neuroinflammation in specific regions may contribute to sickness behaviors that overlap with the symptoms of MDE.

Scientists report that raising levels of the life-extending protein klotho can protect against learning and memory deficits in a mouse model of Alzheimer’s disease.

Remarkably, this boost in cognition occurred despite the accumulation of Alzheimer-related toxins in the brain, such as amyloid-beta and tau.

Alzheimer’s patients have brains with significantly more genetic variation than the brains of those without the disease, according to a study led by scientists at The Scripps Research Institute.

The finding may help scientists track down the mechanism that causes nearly all cases of Alzheimer’s, a mechanism that is not well understood.

The FDA accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release and donepezil hydrochloride tabilized on memantine hydrochloride and donepezil hydrochloride

“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy.  Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer’s disease.”

NCRAD offers genetic samples and data vital to Alzheimer’s research

Identifying the genes involved in Alzheimer’s disease and related dementias is of course no easy task. From among the thousands of gene candidates in the human genome, we need to determine which are involved in onset and progression, and which increase risk or offer protection.